148 related articles for article (PubMed ID: 34593306)
1. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
2. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
3. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
4. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
[TBL] [Abstract][Full Text] [Related]
5. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Eto T; Karasuyama Y; González V; Del Campo García A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
[TBL] [Abstract][Full Text] [Related]
6. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
7. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
[TBL] [Abstract][Full Text] [Related]
9. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
10. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
11. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of charge variants of infliximab biosimilar HS626.
Yuan JJ; Gao D; Hu F; Shi Y; Wu ZH; Hu CQ; Huang XD; Fang WJ; Zhang HT; Wang HB
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122485. PubMed ID: 33360415
[TBL] [Abstract][Full Text] [Related]
13. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab.
Schwabe C; Cole A; Espigares-Correa A; Beydon ME; Florez-Igual A; Queiruga-Parada J
Pharmacol Res Perspect; 2023 Apr; 11(2):e01070. PubMed ID: 36914963
[TBL] [Abstract][Full Text] [Related]
15. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
Fei M; Zhang Q; Zhang L; Zhu X; Du C; Zhang Z
J Pharm Biomed Anal; 2023 Jan; 223():115121. PubMed ID: 36308924
[TBL] [Abstract][Full Text] [Related]
18. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
[TBL] [Abstract][Full Text] [Related]
20. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]